Author:
Gallardo-Alvarado Lenny,Cantú-de León David,Ramirez-Morales Rebeca,Santiago-Concha Gabriel,Barquet-Muñoz Salim,Salcedo-Hernandez Rosa,Reyes Cinthya,Perez-Alvarez Sandra,Perez-Montiel Delia,Perez-Plasencia Carlos,Trejo-Duran Elizabeth,Galicia Juan Pablo
Abstract
Abstract
Background
Even with different histologic origins, squamous cell carcinoma (SCC) and adenocarcinoma (AC) are considered a single entity, and the first-line treatment is the same. Locally advanced disease at the diagnosis of cervical cancer is the most important prognostic factor, the recurrence rate is high, making it necessary to evaluate prognostic factors other than clinical or radiological staging; histology could be one of them but continues to be controversial. The aim of this study was to evaluate tumor histology as a prognostic factor in terms of treatment outcomes, disease-free survival (DFS) and overall survival (OS) in a retrospective cohort of patients with Locally Advanced Cervical Carcinoma (LACC).
Methods
The records of 1291patients with LACC were reviewed, all of them were treated with 45–50 Gy of external beam radiotherapy with concurrent chemotherapy and brachytherapy. A descriptive and comparative analysis was conducted. Treatment response was analyzed by the chi-square test; DFS and OS were calculated for each histology with the Kaplan–Meier method and compared with the log-rank test; and the Cox model was applied for the multivariate analysis.
Results
We included 1291 patients with LACC treated from 2005 to 2014, of which 1154 (89·4%) had SCC and 137 (10·6%) had AC. Complete response to treatment was achieved in 933 (80·8%) patients with SCC and 113 (82·5%) patients with AC. Recurrence of the disease was reported in 29·9% of SCC patients and 31·9% of AC patients. Five-year DFS was 70% for SCC and 62·2% for AC. The five-year OS rates were 74·3% and 60% for SCC and AC, respectively. The mean DFS was 48·8 months for SCC vs 46·10 for AC (p = 0·043), the mean OS was 50·8 for SCC and 47·0 for AC (p = 0·002).
Conclusion
Our findings support the hypothesis that SCC and AC are different clinical entities.
Trial Registration
NCT04537273.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference43 articles.
1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I BF. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. 2018. Available from: https://gco.iarc.fr/today
2. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143:22–36. https://doi.org/10.1002/ijgo.12611.
3. Musselwhite LW, Oliveira CM, Kwaramba T, de Paula Pantano N, Smith JS, Fregnani JH, et al. Racial/Ethnic Disparities in Cervical Cancer Screening and Outcomes. Vol. 60, Acta Cytologica. S. Karger AG; 2016. p. 518–26.
4. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Vol. 393, Lancet. 2019. p. 169–82.
5. Rose PG. Locally advanced cervical cancer. Curr Opin Obstet Gynecol. 2001;13(1):65–70.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献